IP Library Patent Application 17938284
Patent Application
App. No. 17/938,284

DEVICES, SYSTEMS AND METHODS FOR ULTRA-LOW VOLUME LIQUID BIOPSY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/938,284
Abstract

Provided herein are devices, systems, kits and methods for obtaining genetic information from cell-free fetal nucleic acids in ultra-low amounts of biological samples. Due to the convenience of obtaining ultra-low amounts of samples, devices, systems, kits and methods can be at least partially employed at a point of need.

Claims (34)

1 . A method comprising:

(a) obtaining or providing capillary blood comprising cell-free nucleic acids obtained from a subject;

(b) separating plasma or serum from the capillary blood or a portion thereof, thereby generating a plasma or serum sample;

(c) extracting cell-free nucleic acids from the plasma or serum sample; and

(d) detecting an overrepresentation, an underrepresentation, or a normal representation of at least one target nucleic acid sequence in the cell-free nucleic acids.

2 . The method of claim 1 , wherein the extracting of (c) comprises binding the cell-free nucleic acids to a solid support.

3 . The method of claim 2 , wherein the solid support is selected from the group consisting of: a bead, a nanoparticle, a magnetic particle, a chip, a microchip, a fibrous strip, a polymer strip, a membrane, a matrix, a column, a plate, and any combination thereof.

4 . The method of claim 2 , further comprising, eluting the cell-free nucleic acids from the solid support.

5 . The method of claim 4 , further comprising, purifying the cell-free nucleic acids.

6 . The method of claim 1 , wherein the separating of (b) comprises centrifuging the capillary blood, filtering the capillary blood, or both.

7 . The method of claim 1 , wherein the detecting of (d) comprises sequencing the at least one target sequence in the cell-free nucleic acids.

8 . The method of claim 1 , wherein the plasma or serum sample is generated upon or after obtaining the capillary blood sample from the subject.

9 . The method of claim 1 , wherein a total volume of the capillary blood is from about 5 μL to about 1 mL.

10 . A method comprising:

(a) obtaining or providing a capillary blood sample comprising cell-free nucleic acids obtained from a subject;

(b) enriching for cell-free nucleic acids thereby generating enriched cell-free nucleic acids; and

(c) detecting an overrepresentation, an underrepresentation, or a normal representation of at least one target sequence in the enriched cell-free nucleic acids.

11 . The method of claim 10 , wherein the enriching comprises removing a first amount of blood from the capillary blood sample.

12 . The method of claim 10 , wherein the enriching comprises enriching for a target sequence present in the cell-free nucleic acids.

13 . The method of claim 10 , wherein the enriching comprises enriching for fetal cell-free nucleic acids.

14 . The method of claim 10 , wherein the enriching comprises removing white blood cells and/or cellular nucleic acids from the capillary blood sample.

15 . The method of claim 10 , wherein a total volume of the capillary blood is from about 5 μL to about 1 mL.

16 . A method comprising:

(a) obtaining or providing capillary blood comprising cell-free nucleic acids obtained from a subject;

(b) separating plasma or serum from the capillary blood or a portion thereof;

(c) extracting cell-free nucleic acids from the plasma or serum;

(d) detecting at least one target nucleic acid sequence present in the cell-free nucleic acids; and

(e) identifying one or more genetic or chromosomal abnormalities based on the detecting of (d).

17 . The method of claim 16 , wherein the detecting of (d) comprises sequencing the at least one target nucleic acid sequence.

18 . The method of claim 16 , wherein the subject is pregnant with a fetus.

19 . The method of claim 18 , wherein the cell-free nucleic acids comprise fetal cell-free nucleic acids.

20 . The method of claim 19 , wherein the one or more genetic or chromosomal abnormality comprises a fetal aneuploidy or a fetal chromosomal abnormality.

21 . The method of claim 16 , wherein the subject has, is suspected of having, or is at risk of developing cancer.

22 . The method of claim 16 , wherein the capillary blood is obtained from the subject by use of a transdermal puncture device.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2025
From: JUNO DIAGNOSTICS, INC.
To: NUCLEIX LTD.
Reel/Frame 070661/0686 →
RELEASE OF SECURITY INTEREST Recorded Aug 2, 2024
From: WILSON SONSINI GOODRICH & ROSATI, PROFESSIONAL CORPORATION
To: JUNO DIAGNOSTICS, INC.
Reel/Frame 068168/0057 →
SECURITY INTEREST Recorded Sep 1, 2023
From: JUNO DIAGNOSTICS, INC.
To: WILSON SONSINI GOODRICH & ROSATI, PROFESSIONAL CORPORATION
Reel/Frame 064803/0869 →